Ritter Pharmaceuticals
Market Cap
US$1.8m
Last Updated
2019/12/07 00:30 UTC
Data Sources
Company Financials +
Executive Summary
Ritter Pharmaceuticals, Inc. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases.
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Ritter Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RTTR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
12.0%
RTTR
1.2%
US Pharmaceuticals
-0.3%
US Market
1 Year Return
-75.3%
RTTR
-0.1%
US Pharmaceuticals
18.6%
US Market
Return vs Industry: RTTR underperformed the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: RTTR underperformed the US Market which returned 18.6% over the past year.
Shareholder returns
| RTTR | Industry | Market | |
|---|---|---|---|
| 7 Day | 12.0% | 1.2% | -0.3% |
| 30 Day | -23.1% | -1.1% | 2.2% |
| 90 Day | -82.8% | 7.5% | 5.6% |
| 1 Year | -75.3%-75.3% | 2.5%-0.1% | 21.1%18.6% |
| 3 Year | -99.3%-99.3% | 31.3%21.9% | 45.6%36.2% |
| 5 Year | n/a | 25.8%12.5% | 71.1%52.2% |
Price Volatility Vs. Market
How volatile is Ritter Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Do Institutions Own Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Shares?1 month ago | Simply Wall St
Can Ritter Pharmaceuticals (NASDAQ:RTTR) Fund Its Growth Plans?3 months ago | Simply Wall St
Should You Be Concerned About Ritter Pharmaceuticals, Inc.'s (NASDAQ:RTTR) Historical Volatility?Valuation
Is Ritter Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Ritter Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Ritter Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of RTTR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Ritter Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
8.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RTTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RTTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RTTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if RTTR's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if RTTR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RTTR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Ritter Pharmaceuticals performed over the past 5 years?
-25.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RTTR is currently unprofitable.
Growing Profit Margin: RTTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RTTR is unprofitable, and losses have increased over the past 5 years at a rate of -25.8% per year.
Accelerating Growth: Unable to compare RTTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RTTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: RTTR has a negative Return on Equity (-25931.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Ritter Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RTTR's short term assets ($2.7M) do not cover its short term liabilities ($2.8M).
Long Term Liabilities: RTTR's short term assets ($2.7M) exceed its long term liabilities ($10.3K).
Debt to Equity History and Analysis
Debt Level: RTTR is debt free.
Reducing Debt: RTTR currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Inventory Level: RTTR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if RTTR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RTTR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RTTR has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.7% each year
Next Steps
Dividend
What is Ritter Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RTTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RTTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RTTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RTTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RTTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Ritter Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
1.9yrs
Average management tenure
CEO
Andrew Ritter (36yo)
1.5yrs
Tenure
US$2,646,857
Compensation
Mr. Andrew J. Ritter Co-founded Ritter Pharmaceuticals, Inc in 2007 and has been the President since 2008. Mr. Ritter is Chief Executive Officer of Ritter Pharmaceuticals, Inc. since June 27, 2018. He has  ...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD2.65M) is above average for companies of similar size in the US market ($USD508.62K).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.9yrs
Average Tenure
55.5yo
Average Age
Experienced Management: RTTR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Age and Tenure
8.0yrs
Average Tenure
60.5yo
Average Age
Experienced Board: RTTR's board of directors are considered experienced (8 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.5%.
Management Team
John Beck (59yo)
Chief Financial Officer
- Tenure: 1.6yrs
- Compensation: US$935.01k
Ellen Mochizuki (52yo)
Consultant
- Tenure: 2.2yrs
Andrew Ritter (36yo)
Co-Founder
- Tenure: 1.5yrs
- Compensation: US$2.65m
Ira Ritter (70yo)
Co-Founder
- Tenure: 11.9yrs
- Compensation: US$1.35m
Board Members
Paul Maier (71yo)
Independent Director
- Tenure: 4.7yrs
- Compensation: US$46.04k
Matt Foehr (46yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$44.35k
Noah Doyle (51yo)
Director
- Tenure: 11.3yrs
- Compensation: US$33.94k
Warren Grundfest
Member of Medical Advisory Board
- Tenure: 0yrs
Byron Cryer
Member of Medical Advisory Board
- Tenure: 0yrs
Andrew Ritter (36yo)
Co-Founder
- Tenure: 1.5yrs
- Compensation: US$2.65m
Ira Ritter (70yo)
Co-Founder
- Tenure: 11.9yrs
- Compensation: US$1.35m
Dennis Savaiano
Member of Medical Advisory Board
- Tenure: 0yrs
Todd Klaenhammer
Member of Medical Advisory Board
- Tenure: 0yrs
William Merino (76yo)
Independent Director
- Tenure: 2.9yrs
- Compensation: US$40.54k
Company Information
Ritter Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ritter Pharmaceuticals, Inc.
- Ticker: RTTR
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.846m
- Shares outstanding: 10.16m
- Website: https://www.ritterpharmaceuticals.com
Number of Employees
Location
- Ritter Pharmaceuticals, Inc.
- 1880 Century Park East
- Suite 1000
- Los Angeles
- California
- 90067
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RTTR | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jun 2015 |
| 7R9A | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2015 |
Biography
Ritter Pharmaceuticals, Inc. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Its lead product candidate is RP-G28, an or ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/07 00:30 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.